临床外科杂志 ›› 2021, Vol. 29 ›› Issue (7): 687-690.doi: 10.3969/j.issn.1005-6483.2021.07.027

• • 上一篇    下一篇

胰腺癌免疫治疗现状及进展

  

  1. 430022 武汉,华中科技大学同济医学院附属协和医院胰腺外科
  • 出版日期:2021-07-20 发布日期:2021-07-20

Current status and progress of immunotherapy for pancreatic cancer

  1. Department of Pancreatic Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
  • Online:2021-07-20 Published:2021-07-20

摘要: 胰腺癌是一种消化系统中恶性程度极高的疾病,到目前为止,手术切除仍然是治疗胰腺癌的主要手段,但就诊时仅约20%的胰腺癌病人可行手术治疗。即使采取手术治疗、放化疗、生物治疗及靶向治疗等综合治疗措施,胰腺癌病人总体生存率近十年来并未得到明显改善。近年来免疫治疗在肿瘤治疗方面取得了重大突破,癌症免疫治疗现已被公认为与手术、放疗和化疗并列的癌症治疗的第四支柱,在胰腺癌治疗方面也有较多研究,但结果不尽人意。本文就胰腺癌的免疫治疗的现状和可能前景等方面进行综述。

关键词: 胰腺癌, 免疫微环境, 免疫检查点抑制剂, 溶瘤病毒, 外泌体

Abstract: Pancreatic cancer is a highly malignant disease in the digestive system.So far,surgical resection is still the primary treatment for pancreatic cancer,but only about 20% of pancreatic cancer patients can be treated with surgery.Even with comprehensive treatment measures such as surgery,radiotherapy and chemotherapy,biological therapy,and targeted therapy,the overall survival rate of pancreatic cancer patients has not been significantly improved in the past ten years.In recent years,immunotherapy has made breakthroughs in tumor treatment.Cancer immunotherapy has now been recognized as the fourth pillar of cancer treatment alongside surgery,radiotherapy,and chemotherapy.There are also many studies in the treatment of pancreatic cancer,but the results are not satisfactory.This article reviews the current status and possible prospects of immunotherapy for pancreatic cancer.

Key words: pancreatic cancer, immune microenvironment, immune checkpoint inhibitor, oncolytic virus, exosomes

[1] 辛国军 王建承 翁原驰 张俊. 全胰腺切除术9例临床疗效分析[J]. 临床外科杂志, 2021, 29(7): 619-621.
[2] 熊光冰 王敏 朱峰 秦仁义. 液态活检在胰腺癌早期诊断中的作用[J]. 临床外科杂志, 2021, 29(7): 679-683.
[3] 李凡, 管维. 肾癌诊疗相关进展[J]. 临床外科杂志, 2021, 29(2): 101-104.
[4] 刘丹希 孙备. 美国国家综合癌症网络临床实践指南:胰腺癌(2020V1)更新解读[J]. 临床外科杂志, 2021, 29(1): 20-22.
[5] 张涛, 孙备. 2019年NCCN胰腺癌临床实践指南(V2 版)更新解读[J]. 临床外科杂志, 2020, 28(1): 8-11.
[6] 石乔, 刘垒, 张晓艺, 荣愈平, 熊星铖, 常剑, 王卫星, 陶京. 国内应用吉西他滨联合高强度聚焦超声治疗中晚期胰腺癌疗效的Meta分析 [J]. 临床外科杂志, 2019, 27(8): 680-683.
[7] 刘淞淞, 王槐志. 长链非编码RNA在胰腺癌转移中的研究进展[J]. 临床外科杂志, 2019, 27(12): 1099-1101.
[8] 王鑫龙, 孙备. 中国抗癌协会胰腺癌综合诊治指南(2018版)更新解读[J]. 临床外科杂志, 2019, 27(1): 21-24.
[9] 胡嵩 李晓明 朱毅等. 多肿瘤标志物蛋白芯片在胰腺癌手术前后的应用评价 [J]. 临床外科杂志, 2013, 21(4): 303-304.
[10] 廖泉 赵建国 . 胰腺癌的分子生物学治疗进展[J]. 临床外科杂志, 2012, 20(1): 7-7.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 李光焰;张安平;王祥峰;等. 直肠癌切除术后吻合口狭窄14例分析[J]. 临床外科杂志, 2016, 24(10): 772 .
[2] 肖国栋;刘国辉. 跗骨窦切口联合经皮置钉技术微创治疗跟骨骨折的临床疗效分析[J]. 临床外科杂志, 2016, 24(10): 783 .
[3] 李阳;胡元祥;胡季明;等. 甲状腺结核11例临床分析[J]. 临床外科杂志, 2016, 24(11): 888 .
[4] 柯文波;李童;郑启昌. ω-3多不饱和脂肪酸对肝癌患者术后免疫代谢的影响[J]. 临床外科杂志, 2016, 24(12): 905 .
[5] 谭海洋;罗良弢;严想元. 肠内营养与肠外营养在腹腔镜胃肠道肿瘤患者术后早期应用的临床研究[J]. 临床外科杂志, 2016, 24(12): 910 .
[6] 刘智化;陈坚;刘绪舜. 超声引导下冷循环微波消融治疗甲状腺微小癌的临床价值[J]. 临床外科杂志, 2016, 24(12): 934 .
[7] 邹长林;许州;刘超;等. 单侧额下入路显微切除大型及巨大型嗅沟脑膜瘤[J]. 临床外科杂志, 2016, 24(12): 946 .
[8] 杨晓辉;郑淑月;马云改;等. 医用臭氧联合类固醇激素治疗慢性腰椎间盘源性疼痛临床分析[J]. 临床外科杂志, 2016, 24(12): 954 .
[9] 杨新;吴会生;王焱林. 纳美芬在脊柱侧弯矫形术术中唤醒中的应用[J]. 临床外科杂志, 2016, 24(12): 957 .
[10] 王友伢 徐明 王现国等 . 原发性肺纤维肉瘤一例 [J]. 临床外科杂志, 2016, 24(4): 262 .